<DOC>
	<DOCNO>NCT00963534</DOCNO>
	<brief_summary>In phase I : Establishing maximally tolerate dose lenalidomide combination bendamustine rituximab . In phase II : Evaluation progression free survival treatment lenalidomide , bendamustine rituximab</brief_summary>
	<brief_title>Lenalidomide , Bendamustine Rituximab First-line Therapy Patients Over 65 Years With Mantle Cell Lymphoma .</brief_title>
	<detailed_description>This trial consist phase I portion phase II portion . In phase I , MTD lenalidomide determine , start 5 mg/day give maximally 25 mg/day . In combination treatment , bendamustine rituximab give fixed dos . The phase I portion follow sequential dose escalation , 3+3 design . Initially , three subject start treatment dose regimen 1 ( 5 mg/day ) . After third subject complete two cycle treatment , DLT occur , next group three subject treat next dose level lenalidomide ( 10 mg/day ) . If one three initial subject experience DLT , cohort expand six subject . If less two six subject experience DLT , next high dose group initiate . If two subject experience DLT , high dose level test MTD dose exceed . Additional subject enrol MTD phase II portion trial . The described treatment lenalidomide , bendamustine rituximab give 6 cycle , cycle length 22 day . Lenalidomide give day 1-21 , bendamustine day 1-2 rituximab day 1 . During follow maintenance treatment , single treatment lenalidomide give dose lenalidomide ( 25 mg/day ) 7 cycle , whether phase I phase II portion trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Age 65 year , age 65 year , unable tolerate high dose chemotherapy autologous stem cell support Histologically confirm mantle cell lymphoma , stage IIIV time diagnosis No previous treatment lymphoma except radiotherapy one cycle chemotherapy regimen lymphoma WHO Performance Status 03 Written inform concent Female subject childbearing potential must agree use able comply , effective contraception without interruption , 4 week start study drug , study drug therapy 4 week end study drug therapy Male subject must agree use condom throughout study drug therapy partner childbearing potential , contraception , agree donate semen study drug therapy one week end study drug therapy All subject must agree abstain donate blood take study drug therapy one week follow discontinuation , agree share study medication another person Impaired liver function ANC le 1.0 x 10 9 , unless cause bone marrow infiltration lymphoma Platelet count le 60 x 10 9 , unless cause bone marrow infiltration lymphoma Creatinine clearance 50 ml/min ( cockcroft formula ) ) Known HIV positivity Known seropositivity HCV , HBsAG , antiHBc , active infection uncontrolled treatment Psychiatric illness condition could interfere subjectÂ´s ability understand requirement study Requirement corticosteroid therapy dose 10 mg prednisolone/day Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Nordic Lymphoma Group</keyword>
	<keyword>MTD lenalidomide</keyword>
	<keyword>Untreated patient</keyword>
	<keyword>Patients mantle cell lymphoma , age 65 year</keyword>
</DOC>